Microbial testing for freeze-dried cosmetic peptides and reconstituted products

Do not infer sterility from a dry appearance, a sealed vial or the word lyophilized. A cosmetic ingredient purchase needs a defined microbiological specification and evidence appropriate to its intended use. FDA identifies contaminated raw materials and water, inadequate preservation and poorly protective packaging among routes by which cosmetics can become contaminated.

Start the enquiry by stating whether the material will enter a factory formulation or a cosmetic kit mixed by the end user. Those are different product situations. Ask what material the supplied report describes: the peptide ingredient, a blend, a filled dry vial or a finished formulation. Keep that identity beside the batch number in the receiving record. If the supplier uses the word sterile, request the supporting scope and evidence for specialist review. A microbial count report alone should not be converted into a sterility claim on a product page or label.

Request the test method, units, sample quantity and result for each agreed parameter. Keep quantitative counts separate from tests reported as presence or absence in a stated quantity. The laboratory should explain any abbreviation and whether the method is suitable for the submitted material. A bare "pass" cannot be checked against a purchase specification without the criteria it refers to.

As a fictional documentation example, compare "yeast and mould: conforms" with a report that identifies the method, batch, tested quantity, result and agreed limit. The second record allows a reviewer to trace the decision, even though the appropriate limit still needs technical approval. This guide deliberately supplies no universal colony-count limit for peptide powder. Ask the laboratory and responsible quality team to select the tests for the actual ingredient and application, and record who approves an exception before accepting a report with missing fields.

Evaluate the mixed formulation under its intended conditions of preparation, storage and use. The original powder report describes the tested powder sample. It does not answer how the final mixture resists contamination during use. FDA notes that adding water can introduce microorganisms and dilute preservatives in cosmetics.

ISO 11930:2019 provides a framework for evaluating antimicrobial protection using preservation efficacy testing, microbiological risk assessment or both. Its public scope primarily addresses water-soluble or water-miscible cosmetics and distinguishes products assessed as microbiologically low risk. It also lists Amendment 1:2022. For a peptide kit, send the laboratory the proposed mixing instructions, diluent, packaging and intended period of use. Ask which product state and assessment are covered by its quotation. Do not claim compliance from the ingredient name or a test on a different base formula. The finished cosmetic needs an assessment that matches the product actually supplied.

Leave the use period unassigned until the responsible team has supporting evidence for the actual product. A convenient marketing statement such as "use within seven days" is still a product instruction that needs justification. For an OEM project, write the proposed instruction as a question in the development brief, then link the final wording to the approved assessment.

Consider two hypothetical briefs using the same dry ingredient. One proposes a single-use cosmetic portion; the other proposes a dropper bottle opened repeatedly over several weeks. Do not reuse the first brief's assessment without checking the second scenario. Record who supplies the diluent, who fills the packaging and who owns the finished-product evaluation. If any of those details changes, return the use instructions for review. These are planning examples, not evidence that either format is microbiologically safe or suitable for a particular peptide.